New, highly potent and non-toxic, chromone inhibitors of the human breast cancer resistance protein ABCG2
作者:Amanda do Rocio Andrade Pires、Florine Lecerf-Schmidt、Nathalie Guragossian、Jaqueline Pazinato、Gustavo Jabor Gozzi、Evelyn Winter、Glaucio Valdameri、Alexander Veale、Ahcène Boumendjel、Attilio Di Pietro、Basile Pérès
DOI:10.1016/j.ejmech.2016.05.053
日期:2016.10
Breast cancer resistance protein (BCRP/ABCG2) is one of the major transporters involved in the efflux of anticancer compounds, contributing to multidrug resistance (MDR). Inhibition of ABCG2-mediated transport is then considered a promising strategy for overcoming MDR in tumors. We recently identified a chromone derivative, namely MBL-II-141 as a selective ABCG2 inhibitor, with relevant in vivo activity
乳腺癌抗性蛋白(BCRP / ABCG2)是参与抗癌化合物外排的主要转运蛋白之一,有助于多药耐药性(MDR)。然后,认为抑制ABCG2介导的转运可克服肿瘤中的MDR。我们最近鉴定了一种色酮衍生物,即MBL-II-141,作为一种选择性ABCG2抑制剂,具有相关的体内活性。在这里,我们报告了MBL-II-141的药物代谢,目的是鉴定关键药效学元素,以设计更有效的选择性和无毒抑制剂。通过使用简单且负担得起的化学方法对MBL-II-141进行合理的结构修饰,我们获得了活性高且易于制备的ABCG2抑制剂。在研究的化合物中,衍生物4a,发现其效价比MBL-II-141强3倍。它与参考抑制剂Ko143类似地有效,但具有较低的固有细胞毒性优势,因此构成有史以来报道的显示出极高治疗率的最佳ABCG2抑制剂。